CVS Health (NYSE:CVS) Raised to “Buy” at Edward Jones

CVS Health (NYSE:CVS) was upgraded by research analysts at Edward Jones from a “hold” rating to a “buy” rating in a research note issued on Thursday, MarketBeat.com reports.

Other analysts also recently issued research reports about the stock. Royal Bank of Canada cut their price target on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a report on Friday, November 15th. TD Cowen raised their target price on CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Piper Sandler decreased their price target on CVS Health from $72.00 to $64.00 and set an “overweight” rating on the stock in a research note on Monday, November 25th. StockNews.com downgraded CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft raised shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research note on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $68.12.

CVS Health Price Performance

NYSE:CVS opened at $56.53 on Thursday. The stock has a 50 day moving average price of $51.27 and a 200 day moving average price of $56.17. The stock has a market cap of $71.13 billion, a PE ratio of 14.35, a P/E/G ratio of 0.62 and a beta of 0.59. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. CVS Health has a one year low of $43.56 and a one year high of $80.75.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. During the same quarter in the previous year, the firm earned $2.21 EPS. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities research analysts expect that CVS Health will post 5.18 EPS for the current fiscal year.

Institutional Trading of CVS Health

Hedge funds have recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. acquired a new stake in shares of CVS Health in the 3rd quarter valued at $25,000. Livelsberger Financial Advisory acquired a new stake in shares of CVS Health during the 3rd quarter worth about $31,000. Legacy Investment Solutions LLC purchased a new stake in CVS Health during the third quarter worth approximately $31,000. Reston Wealth Management LLC acquired a new position in CVS Health in the third quarter valued at approximately $32,000. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in CVS Health during the third quarter worth approximately $33,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.